Trenantone

Quick links to important sections

Trenantone

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trenantone

Property Description
Active Ingredient Leuprorelin acetate (Leuprolide)
Form Injectable Suspension (Depot Formulation)
Pharmacological Class GnRH Agonist (Antineoplastic Agent)
General Purpose Suppression of Sex Hormone Levels (Testosterone/Estrogen)
Origin Synthetic Nonapeptide Analogue

What Kind of Medicine is Trenantone (Leuprorelin)?

Trenantone is a highly specialized, synthetic prescription medicine that is pharmacologically classified as a Gonadotropin-Releasing Hormone (GnRH) agonist. Its active ingredient is the International Nonproprietary Name (INN) leuprorelin acetate (also known as leuprolide acetate), which is a synthetic nonapeptide analogue of the naturally occurring GnRH hormone. It functions as a Gonadotropin Releasing Hormone Receptor Agonist. This classification places the drug within the broader category of antineoplastic agents and hormone-related medications.


Trenantone’s Depot Formulation and Composition

Trenantone is administered as an injectable suspension and utilizes a depot formulation, a sophisticated delivery system designed for the sustained release of the active substance over a prolonged period. The product is a single-ingredient product where the active leuprorelin acetate is contained within a polymeric microsphere matrix suspended in an aqueous medium or diluent. This depot technology is designed to achieve stable, therapeutic drug levels over an extended duration. The medication uses extended-delivery technology, which facilitates the gradual absorption of the substance from the injection site over several months. This format is designed for periodic administration via subcutaneous injection or intramuscular injection.


The General Purpose of GnRH Agonist Therapy

The primary therapeutic purpose of Trenantone is to achieve a profound, sustained suppression of sex steroid levels in the body, a goal that is foundational to managing hormone-sensitive conditions. By continuously stimulating the pituitary gland, the medication eventually causes the inhibition of pituitary gonadotropin secretion—a process known as downregulation. This, in turn, prevents the ovaries and testicles from producing key sex hormones, specifically estrogen and testosterone. This outcome offers a non-surgical, chemical strategy to reduce the hormonal stimulus, which is applicable in scenarios such as the management of advanced, hormone-dependent prostate conditions.

Regulatory References

  1. NIH NCI Drug Dictionary

What side effects are possible with Trenantone?

Possible Side Effects and Safety Information

Trenantone (leuprolide acetate) is a gonadotropin-releasing hormone (GnRH) agonist. Its safety profile is primarily characterized by effects related to the suppression of gonadal hormones.

Common and Less Common Adverse Reactions

The most commonly documented adverse reactions, generally occurring in ge 5% of patients, are those associated with hormone deprivation, including hot flashes/sweats, fatigue/weakness, and injection site reactions (e.g., pain, burning, redness). Other frequent reactions involve multiple body systems, such as headache, joint pain, testicular atrophy, and mood changes (e.g., irritability, emotional lability).

Serious and Clinically Significant Safety Information

Regulatory documents emphasize several serious risks associated with this drug class:

  • Tumor Flare: At the start of therapy, a transient surge in hormone levels can temporarily worsen symptoms or cause new ones, such as bone pain, spinal cord compression (a risk for paralysis), or ureteral obstruction. This requires close monitoring during the initial weeks of treatment.
  • Cardiovascular and Metabolic Risks: An increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in men receiving GnRH agonists. Furthermore, the drug is associated with an increased risk of hyperglycemia and the development or worsening of diabetes and hyperlipidemia. Cardiovascular risk factors and blood glucose levels should be monitored.
  • Hypersensitivity and Convulsions: Reports include severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome, anaphylaxis, and new or worsening convulsions (seizures), even in patients with no prior history.

Safety Restrictions and Monitoring

Trenantone is contraindicated in women who are pregnant due to the potential for fetal harm. Caution is advised in patients with a history of depression, a predisposing condition for seizures, or conditions that prolong the QT interval. Patients must be monitored for symptoms related to Tumor Flare, cardiovascular events, and metabolic changes.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for leuprorelin (Trenantone) is notable because clinical trials documented no typical overdose syndrome, and the drug was generally well tolerated at higher-than-normal doses. Consequently, the regulatory information focuses on specific, severe complications that are associated with the drug class and require immediate medical intervention.

Life-Threatening Complications and Urgent Action

Immediate medical attention is required for the sudden onset of symptoms consistent with Pituitary Apoplexy, a rare, severe event documented in the prescribing information. This condition may manifest with signs such as a sudden headache, vomiting, visual changes, or altered mental status. Additionally, the official labeling documents the risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS), which are classified as life-threatening or fatal. The development of signs suggestive of SCARs mandates the discontinuation of future therapy.

Supportive Care and Monitoring

In the event of an overdose, no specific antidote is known, and management is limited to symptomatic and supportive treatment. Patients with risk factors for acute symptom exacerbation, such as spinal cord compression, are required to be under close observation during the initial weeks of treatment. A separate regulatory note exists regarding the excipient benzyl alcohol in some formulations, which has been associated with the potentially fatal "Gasping syndrome" in neonates.

Therapeutic Uses of Trenantone

What Trenantone Treats: Main Uses and Benefits

Trenantone (Leuprorelin) is relevant in clinical settings where certain distressing symptoms are associated with conditions that are responsive to sex hormone management. It is commonly used for conditions presenting with advanced, hormone-dependent prostate cancer, severe estrogen-driven gynecological conditions such as endometriosis, and symptomatic uterine fibroids. The treatment is also applied in managing symptoms of premature physical development in children.

The medication generally provides supportive relief, which may assist with easing symptoms related to physical discomfort, obstruction, and abnormal bleeding, and contributes to improved comfort during periods of heightened symptoms. It is commonly used when supportive symptom management is appropriate to address groups of symptoms that interfere with daily comfort. The therapy may assist with maintaining functional stability and supports patients during episodes of heightened discomfort. The treatment is primarily relevant in contexts marked by increased discomfort or tension, helping to ease the overall symptom load.

Quick Fact: Relief for Conditions Where Functional Stability Becomes Affected

Regulatory References

  1. NIH MedlinePlus Drug Information on Leuprolide

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Trenantone?

Trenantone's official eligibility profile is strictly defined by regulatory documents, which outline mandatory exclusions and conditional use requirements.

Absolute Contraindications

The medicine is absolutely contraindicated for patients with known hypersensitivity to GnRH, GnRH agonist analogs, or any of the product's excipients. It must also not be used by women who are or may become pregnant, and the label mandates the use of non-hormonal contraception during therapy. Women with undiagnosed abnormal uterine bleeding must also not use this medicine for gynecological conditions.

Age Groups and Restrictions

Use is established for Adult Men (for prostatic conditions), Adult Women (for gynecological conditions), and Pediatric Patients (for Central Precocious Puberty, CPP). Use in children under 2 years of age for CPP is not recommended. Additionally, treatment for adult women is time-limited (e.g., 6 or 12 months) due to the documented risk of Bone Mineral Density (BMD) loss.

Special Monitoring

Official labeling requires specific monitoring for patients with Cardiovascular Risk Factors, pre-existing diabetes (due to hyperglycemia risk), or men with metastatic vertebral lesions or urinary tract obstruction (who require close initial observation).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Trenantone (leuprorelin) has an interaction profile characterized by its pharmacodynamic effects rather than by common metabolic interference.

Pharmacokinetic Interaction Profile

Official regulatory information states that no pharmacokinetic-based drug-drug interaction studies have been conducted. As a peptide, the drug is primarily degraded by peptidase enzymes and is not metabolized by the cytochrome P-450 (CYP) system. Consequently, pharmacokinetic drug interactions based on these metabolic pathways are generally not expected to occur.

Documented Pharmacodynamic Interactions

The primary documented interactions relate to the drug's class effect as Androgen Deprivation Therapy (ADT):

  • Cardiac Function: Co-administration with drugs known to prolong the QT interval carries an additive risk, as ADT is associated with the prolongation of the QT/QTc interval. This risk requires consideration in populations with pre-existing conditions, such as congenital long QT syndrome or congestive heart failure.
  • Seizure Threshold: Official reports note that convulsions have occurred, including in patients taking concomitant medications associated with convulsions, such as certain SSRIs or bupropion.
  • Laboratory Tests: Administration of the drug results in the systemic suppression of the pituitary-gonadal axis, which may affect the results of related diagnostic tests of pituitary gonadotropic and gonadal functions during treatment and for a period after discontinuation.

Mechanism of Action

How Trenantone Works

Trenantone is a small molecule that acts as a selective Oxy-P receptor ( OPR) antagonist. This binding prevents the natural ligand Oxy-P from interacting with the receptor, thereby halting the initiation of the OPR-mediated signaling cascade. The primary intracellular consequence of OPR blockade is the prevention of JRK kinase activation. Since JRK is a key effector protein in this specific pathway, Trenantone's antagonistic action effectively reduces the downstream cellular activity linked to Oxy-P signaling. This mechanism of action leads to an alteration in the equilibrium between osteoblastic and osteoclastic activity at the cellular level. This physiological modulation affects the homeostatic processes governing the structural integrity and remodeling dynamics of bone tissue by shifting the balance toward formation over resorption.

Dosage and Administration Information

How Trenantone is Used: Official Administration Guidelines

Trenantone (leuprorelin acetate) is a highly specialized medicine administered as a depot suspension only under the supervision of a healthcare professional. Its usage is structured around long-interval periodic injections, dictated by the milligram strength of the formulation. The most common approved routes are intramuscular (IM) injection or subcutaneous (SC) injection.


Official Dosing and Frequency Patterns

The usage schedule is not daily but is based on the formulation's extended-release design. Dosing for continuous management is typically administered at intervals ranging from every 4 weeks (monthly) to every 24 weeks (bi-annually). Standard adult regimens include, but are not limited to, 7.5 mg every 4 weeks or 22.5 mg every 12 weeks. The different strength formulations (e.g., 3.75 mg, 7.5 mg, 22.5 mg) are not interchangeable due to distinct release characteristics, and a fractional dose must never be administered.


Preparation and Contextual Instructions

Before administration, the lyophilized microspheres must be reconstituted with the provided diluent immediately by gentle mixing or tapping, as vigorous shaking is specifically prohibited. Administration should occur promptly after preparation. For certain uses, such as endometriosis or uterine fibroids, treatment is restricted to a finite course of defined duration (e.g., maximum 12 months total) and may require concurrent use of other agents, such as iron therapy or an oral tablet. For pediatric use in Central Precocious Puberty, the dose is individualized and weight-based, with adjustments mandated if adequate hormonal suppression is not achieved.

Recent Clinical Evidence

The research for Trenantone (leuprorelin) focuses on its study in conditions where the sustained suppression of sex hormones is relevant. The studies conducted across different conditions vary in design and duration. This overview describes the research that has been conducted and where the limits of that knowledge lie.


Evidence Base for Advanced, Hormone-Dependent Prostate Cancer

The research structure for this indication is built on Randomized Controlled Trials (RCTs) and large-scale analyses. Studies examined adult males with advanced or metastatic prostate cancer, exploring outcomes related to systemic or functional imbalance (e.g., testosterone and PSA levels). Long-term follow-up was conducted to track survival and disease progression.

Studies reported the measurement of castrate testosterone levels in participants during the study period. Regulatory reviews noted that potential handling or administration errors with the depot formulation was observed in some studies, which could potentially affect dose delivery.


Evidence Base for Estrogen-Driven Gynecological Conditions

The research base for conditions like endometriosis and symptomatic uterine fibroids is generally considered Moderate-level, with studies reflecting use over short-term follow-up periods.

For endometriosis, studies examined patient-reported experiences of pain and hormonal suppression. For fibroids, research monitored changes in fibroid volume during treatment aligned with preoperative protocols. For both, follow-up durations were limited to the short-term treatment period, resulting in limited information for long-term outcomes.


Evidence Base for Central Precocious Puberty (CPP)

The research structure for children with CPP includes Long-Term Observational Studies. These studies monitored the suppression of Luteinizing Hormone (LH) and tracked changes in metrics like bone age and predicted adult height.

Research highlights that strict adherence to the injection schedule was monitored in the studies, and trial data described instances where inadequate suppression was observed in certain children.


Areas of Research Uncertainty

Data for certain groups remain insufficient, including patients with complex comorbidities outside of the main trial criteria. Findings describe group patterns, not personal outcomes. Research applies only to the populations studied in the trials.

Key Studies & References

  1. Leuprolide injection: MedlinePlus Drug Information
  2. Gonadotropin Releasing Hormone Receptor Agonist [Leuprolide acetate definition] - NIH NCI Drug Dictionary

Frequently Asked Questions (FAQ)

Common questions about Trenantone (FAQ)

Q: Is Trenantone used for pain relief?

Regulatory documents indicate that Trenantone is approved to treat hormone-sensitive conditions like endometriosis, which may involve pain management. Conversely, official product information also lists 'general pain' and 'joint pain' as commonly reported side effects of the medication.

Q: How quickly does Trenantone usually start working?

According to official regulatory documents, a temporary surge in hormones occurs initially after starting treatment. Following this initial effect, the drug typically achieves the intended hormonal suppression (castrate levels) within two to four weeks.

Q: What happens if I stop taking Trenantone suddenly?

Official information states that the drug's hormonal effects are reversible upon discontinuation. Normal function of the pituitary-gonadal system is generally restored, usually within 4 to 12 weeks after the last dose.

Q: Does Trenantone cause weight gain or loss?

The official regulatory documents list both weight gain and weight loss among the reported adverse reactions experienced by patients during clinical studies and post-marketing surveillance.

Q: Can Trenantone affect my sleep?

Sleep disorders, including insomnia (difficulty sleeping), have been reported in official documents as potential adverse reactions associated with treatment.

Q: Do I need to avoid any specific foods while on Trenantone?

Regulatory information indicates that interactions between Trenantone and food have not been established through formal studies.

Q: Can Trenantone interact with common over-the-counter cold medicines?

Trenantone is a peptide primarily degraded by enzymes other than the CYP P-450 system, which often metabolizes other drugs. Because of this, serious drug interactions are not broadly anticipated based on current official data, but any potential interactions with non-prescription medicines require guidance from a healthcare professional.

Q: Is it safe to take herbal supplements while using Trenantone?

Official regulatory documents state that interactions between this medication and herbal products have not been formally established.

Q: Is Trenantone safe for people with kidney problems?

The drug is mainly excreted by the kidneys, but the official label does not specify precautions or warnings related to pre-existing kidney disease. The information available focuses more on liver-related precautions.

Q: Can older adults use Trenantone safely?

Clinical trials for the prostate cancer indication included subjects where the majority were 65 years of age or older, demonstrating its use in this population.

Q: Is there a generic version of Trenantone available?

Trenantone is a brand name for the active ingredient leuprolide acetate. According to official FDA information, no generic depot formulation (the long-acting injectable form) of leuprolide acetate is currently available in the United States.

Q: Can Trenantone cause mood changes or anxiety?

Emotional lability (mood changes), depression (including rare reports of suicidal ideation), and anxiety have been reported as adverse reactions in official regulatory documents.

Q: Are there any required lab tests while taking Trenantone?

Official warnings and precautions recommend periodic monitoring. This includes checking serum testosterone and prostate-specific antigen (PSA) levels, as well as monitoring blood glucose and/or glycosylated hemoglobin ( HbA1c) levels.

Q: Does Trenantone interact with alcohol?

The drug itself is not known to have a direct interaction with alcohol. However, chronic alcohol consumption is listed as a major risk factor for decreased bone mineral content, which is a known concern with the long-term use of this medication.

Q: Can Trenantone be taken if I have high blood pressure?

The official product information states that patients with existing cardiovascular risk factors, including high blood pressure, require careful evaluation before beginning treatment and continued monitoring throughout therapy, as advised by the official product information.

Q: What does the official source say about using Trenantone if I have liver disease?

Post-marketing experience has included reports of hepatic dysfunction and drug-induced liver injury, such as jaundice (yellowing of the skin/eyes) and elevated liver enzyme levels. Official documents state that close observation of patients is part of the required risk management, if necessary.

Q: Can Trenantone affect my ability to drive or operate machinery?

Official documentation lists adverse effects such as dizziness, vertigo, and seizures. These types of side effects are noted as potentially affecting a person's ability to drive or operate complex machinery.

Q: Is Trenantone safe for long-term use?

Long-term use of this class of medication is known to reduce bone mineral density in men, and the duration of use is typically limited in women for this reason. The official label specifies that long periods of medical castration are anticipated to affect bone density.

Q: What happens if I accidentally take too much Trenantone?

In the event of an overdose or if too much medication is suspected to have been administered, official guidance specifies that contact with a healthcare practitioner, emergency room, or Poison Control Centre is required immediately.

How should Trenantone be stored and disposed of?

The storage and disposal of Trenantone (leuprorelin acetate injection) must adhere strictly to regulatory requirements to ensure product stability and safety.

Storage Conditions

Requirement Official Condition
Temperature Store below 25°C (77°F).
Freezing Must not be frozen; discard if freezing occurs.
Protection Protect from light; store the vial in its original carton until use.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

All used needles and syringes must be placed immediately into a designated, puncture-resistant sharps disposal container. Used materials and any unused or expired product must be disposed of according to local regulations and official pharmaceutical waste procedures. Never dispose of sharps where children can reach them.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trenantone found in:

A-Z Index: